Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape


3    Merck    $19.3B    up 3.8%


Global revenue: $48.0B (4th); up 4.3%

R&D spend: $7.7B (4th), down 4.9%; 16% of rev.

Top brands: Singulair ($4.5B); Januvia ($2.1B); ­Zetia ($1.3B): Vytorin ($1.1B)

Planned launches: Vorapaxar (TRA); Tredaptive & MK-0524B (athero.); odanacatib (osteo.)

Promotional spend: $1.3B (3rd); 7.0% of rev.

Patent expirations: Singulair (2012); Avelox (2014); Nasonex (2014)

Merck performed well domestically and globally, thanks in large part to the Januvia diabetes franchise, which now accounts for 76% of the global DPP-IV market. This franchise will keep growing from almost $5.9B (globally) to $9.4B by 2016, Bernstein's Tim Anderson predicts, helping offset top seller Singulair's loss of exclusivity this year and plugging shortfalls in other franchises, like Isentress, which is at risk due to HIV/AIDS competition from Gilead and GSK/Shionogi; Remicade, whose revenues are declining after some control was ceded to partner J&J in 2010; and cholesterol meds Vytorin and Zetia, down about 45% in US sales since the 2008 Enhance study, and which face a renewed threat from generic Lipitor. Whether the ezetimibe franchise gets vindicated by the IMPROVE-IT trial won't impact P&L too much. What matters more is whether late-stage pipeline drugs suvorexant (sleep), odanacatib (osteo.), vorapaxar (TRA) and Tredaptive stay on track.

Back to first page

Page 3 of 21
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters